Floatz logo

Ruxolitinib

Graft Versus Host Disease

Jonathan BrammerSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Graft Versus Host Disease cohort.

Asset / SponsorPhaseRating
Busulfanum
City of Hope Medical Center
Phase 4BBB
Cyclophosphamide
City of Hope Medical Center
Phase 4BBB
Thiotepa
Memorial Sloan Kettering Cancer Center
Phase 4BBB
Nivestim
City of Hope Medical Center
Phase 4BBB
Cyclosporin A
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 49 →

Same molecule, other indications

Ruxolitinib is also rated in:

primary myelofibrosisActive
BBB
Indicative · Phase 4
73 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BB
Indicative · Phase 4
70 / 100
View asset →
acquired polycythemia veraActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →